Analysts Set enGene Holdings Inc. (NASDAQ:ENGN) PT at $26.40

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have earned an average rating of “Buy” from the ten analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $25.89.

ENGN has been the subject of a number of analyst reports. Piper Sandler started coverage on enGene in a research report on Tuesday, February 18th. They issued an “overweight” rating and a $26.00 price target for the company. JMP Securities restated a “market outperform” rating and set a $18.00 target price on shares of enGene in a research note on Monday, December 23rd. UBS Group lowered shares of enGene from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $34.00 to $7.00 in a research report on Friday, February 14th. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a research report on Monday, November 18th. Finally, Raymond James initiated coverage on shares of enGene in a research note on Wednesday, November 27th. They set an “outperform” rating and a $23.00 target price on the stock.

enGene Stock Performance

Shares of NASDAQ ENGN opened at $6.24 on Wednesday. enGene has a 12-month low of $4.42 and a 12-month high of $18.40. The firm has a market capitalization of $276.07 million, a price-to-earnings ratio of -10.76 and a beta of -0.65. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. The firm has a 50 day moving average of $6.77 and a 200 day moving average of $7.19.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. On average, research analysts anticipate that enGene will post -1.56 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fcpm Iii Services B.V. lifted its position in shares of enGene by 11.0% in the fourth quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company’s stock worth $64,057,000 after buying an additional 954,610 shares in the last quarter. VR Adviser LLC increased its position in enGene by 41.5% during the fourth quarter. VR Adviser LLC now owns 5,046,414 shares of the company’s stock valued at $33,559,000 after acquiring an additional 1,480,573 shares during the last quarter. Deep Track Capital LP raised its stake in shares of enGene by 74.8% in the fourth quarter. Deep Track Capital LP now owns 4,557,575 shares of the company’s stock valued at $30,308,000 after acquiring an additional 1,949,942 shares during the period. Blue Owl Capital Holdings LP lifted its holdings in shares of enGene by 3.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company’s stock worth $21,014,000 after acquiring an additional 101,006 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in shares of enGene by 84.7% during the 4th quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company’s stock worth $8,145,000 after purchasing an additional 561,797 shares during the period. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.